{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T11:05:35Z","timestamp":1773831935172,"version":"3.50.1"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.msard.2024.105837","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T21:39:21Z","timestamp":1724449161000},"page":"105837","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Treatment continuation with cladribine at 5 years after initiation in people with multiple sclerosis: A case series and literature review"],"prefix":"10.1016","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5024-3615","authenticated-orcid":false,"given":"Tarunya","family":"Arun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah","family":"Shehu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleanor","family":"Pye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Meehan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2024.105837_bib0001","doi-asserted-by":"crossref","DOI":"10.1177\/17562864231200627","article-title":"Disease activity 4.5\u2009years after starting cladribine: experience in 264 patients with multiple sclerosis","volume":"16","author":"Allen-Philbey","year":"2023","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"suppl 3","key":"10.1016\/j.msard.2024.105837_bib0002","first-page":"968","article-title":"Year 5 treatment continuations and long term effectiveness and safety of oral cladribine in real world practice at a large uk tertiary multiple sclerosis centre: a cohort study","volume":"29","author":"Arun","year":"2023","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2024.105837_bib0003","first-page":"134","article-title":"Outcomes after late cladribine re-dosing in the Australian MSBase cohort [Abstract #P865]","volume":"27","author":"Butzkueven","year":"2021","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2024.105837_bib0004","unstructured":"European Medicines Association, 2017. Mavenclad [cladribine] summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mavenclad-epar-product-information_en.pdf. (Accessed 20 October, 2023)."},{"key":"10.1016\/j.msard.2024.105837_bib0005","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.msard.2024.105837_bib0006","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1177\/1352458517727603","article-title":"Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study","volume":"24","author":"Giovannoni","year":"2018","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2024.105837_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105704","article-title":"Real-world therapy management of patients with multiple sclerosis receiving cladribine tablets beyond year 4 - Results from a German cladribine cohort","volume":"88","author":"Kowarik","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.105837_bib0008","doi-asserted-by":"crossref","first-page":"e24969","DOI":"10.2196\/24969","article-title":"Efficacy of cladribine tablets as a treatment for people with multiple sclerosis: Protocol for the CLOBAS Study (Cladribine, a Multicenter, Long-term Efficacy and Biomarker Australian Study)","volume":"10","author":"Maltby","year":"2021","journal-title":"JMIR Res. Protoc."},{"key":"10.1016\/j.msard.2024.105837_bib0009","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1080\/14656566.2022.2106783","article-title":"Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4","volume":"23","author":"Meuth","year":"2022","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.msard.2024.105837_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104459","article-title":"Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: Systematic literature review of real-world evidence","volume":"69","author":"Oreja-Guevara","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.105837_bib0011","first-page":"795","article-title":"4-year follow-up of multiple sclerosis patients treated with cladribine: clinical outcomes and third-year course [Abstract# EPO-654]","volume":"29","author":"Oreja-Guevara","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2024.105837_bib0012","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/13524585211012227","article-title":"Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres","volume":"28","author":"Pfeuffer","year":"2022","journal-title":"Mult. Scler."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824004140?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824004140?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T07:56:53Z","timestamp":1726387013000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034824004140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":12,"alternative-id":["S2211034824004140"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2024.105837","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment continuation with cladribine at 5 years after initiation in people with multiple sclerosis: A case series and literature review","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2024.105837","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105837"}}